News
Updated and committed to information
NEW DRUG CANDIDATE TO BLOCK TUMOR STEM CELLS TUMOR STEM CELLS
An international consortium led by IRB Barcelona and the company Merus has discovered MCLA-158, an antibody that targets cancer stem cells in solid tumors and
FDA APPROVES ALPELISIB FOR PIK3CA-RELATED OVERGROWTH SPECTRUM
On April 5, 2022, the Food and Drug Administration (FDA) approved alpelisib (Vijoice, Novartis Pharmaceuticals) treatment for adult and pediatric patients aged two years and
RIBOCICLIB PLUS BINIMETINIB FOR PATIENTS WITH WITH NRAS-MUTATED MELANOMA
Patients with melanoma have some relevant mutations, the most frequent being the BRAF mutation (40-60% of patients); this biomarker is also fundamental due to the
PEMIGATINIB FOR PAN-CANCER PATIENTS WITH FGF/FGFR-POSITIVE ADVANCED MALIGNANCIES
This phase I/II trial evaluated the safety, activity, and efficacy of pemigatinib, a selective FGFR 1–3 inhibitor, in patients with refractory advanced malignancies, with or
A NOVEL THIRD-GENERATION EGFR TYROSINE KINASE INHIBITOR ABIVERTINIB FOR EGFR T790M-MUTANT NON–SMALL CELL LUNG CANCER: A MULTICENTER PHASE I/II STUDY
In this phase I/II trial, the authors investigated a novel third-generation EGFR tyrosine kinase inhibitor (TKI), abivertinib, in patients with non-small cell lung cancer and
EGFR AND HER2 EXON 20 INSERTIONS IN SOLID TUMOURS: FROM BIOLOGY TO TREATMENT
Protein tyrosine kinases of the human epidermal growth factor receptor family, including EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung, breast
